With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist. Medications with the brand names Ozempic, Wegovy, Zepbound, and Mounjaro have garnered ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Tirzepatide (15 mg once weekly), a dual agonist targeting GLP-1 and GIP receptors, produced weight loss of up to 17.8% after 72 weeks, and semaglutide (2.4 mg once weekly) produced weight loss of ...

Tiziana’s nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Image: Adobe Stock Kim and colleagues compared outcomes between two matched cohorts of patients who filled a prescription for a GLP-1 within at least 90 days before and after surgery and patients ...